Depomed To Present At Piper Jaffray 2013 Healthcare Conference
NEWARK, Calif., Dec. 2, 2013
NEWARK, Calif., Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today
announced that it will be presenting at the Piper Jaffray 25^th Annual
Healthcare Conference at The New York Palace Hotel in New York City.
The presentation at the Piper conference is scheduled for 12:10 pm EST (9:10
am PST) on Tuesday, December 3, 2013. The presentation will be webcast, and
the webcast can be accessed via the Investor Relations page of the Depomed
website at www.depomed.com. A recording of the webcast will be archived for
30 days on the company's website.
Depomed, Inc. is a specialty pharmaceutical company that commercializes
products for pain and neurology related disorders. Gralise® (gabapentin) is a
once-daily treatment approved for the management of postherpetic neuralgia.
Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal
anti-inflammatory drug indicated for relief of mild to moderate acute pain in
adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to
manage breakthrough pain in adults (18 years of age or older) who are already
routinely taking other opioid pain medicines around-the-clock for cancer pain.
Gralise and other products and product candidates are formulated with
Depomed's proven, proprietary Acuform® drug delivery technology. Additional
information about Depomed may be found at www.depomed.com.
CONTACT: August J. Moretti
Depomed, Inc. 650-462-5900
SOURCE Depomed, Inc.
Press spacebar to pause and continue. Press esc to stop.